ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 58 filers reported holding ONCOCYTE CORP in Q4 2019. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,133,755 | -37.6% | 13,625,022 | -3.8% | 0.42% | -18.3% |
| Q1 2023 | $5,020,488 | -13.4% | 14,166,163 | -21.5% | 0.51% | +69.9% |
| Q4 2022 | $5,794,258 | -56.0% | 18,056,274 | 0.0% | 0.30% | -60.8% |
| Q3 2022 | $13,181,000 | -18.9% | 18,056,274 | 0.0% | 0.76% | -19.1% |
| Q2 2022 | $16,245,000 | -10.8% | 18,056,274 | +47.7% | 0.94% | +59.6% |
| Q1 2022 | $18,214,000 | -31.3% | 12,223,953 | 0.0% | 0.59% | -38.5% |
| Q4 2021 | $26,526,000 | -39.0% | 12,223,953 | 0.0% | 0.96% | -27.4% |
| Q3 2021 | $43,517,000 | -38.0% | 12,223,953 | 0.0% | 1.32% | -39.4% |
| Q2 2021 | $70,165,000 | +10.6% | 12,223,953 | 0.0% | 2.18% | +20.8% |
| Q1 2021 | $63,442,000 | +322.5% | 12,223,953 | +94.6% | 1.81% | +231.1% |
| Q4 2020 | $15,016,000 | +79.4% | 6,282,823 | +4.3% | 0.55% | +26.7% |
| Q3 2020 | $8,371,000 | -26.8% | 6,022,534 | +0.6% | 0.43% | -60.8% |
| Q2 2020 | $11,429,000 | -16.4% | 5,983,724 | +7.3% | 1.10% | -32.3% |
| Q1 2020 | $13,667,000 | +6.6% | 5,578,283 | -2.1% | 1.62% | +43.9% |
| Q4 2019 | $12,817,000 | – | 5,696,576 | – | 1.13% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| BROADWOOD CAPITAL INC | 17,349,945 | $25,851,000 | 1.86% |
| Defender Capital, LLC. | 2,562,130 | $4,001,000 | 1.39% |
| PURA VIDA INVESTMENTS, LLC | 12,223,953 | $18,214,000 | 0.59% |
| Penbrook Management LLC | 578,150 | $861,000 | 0.56% |
| ACT CAPITAL MANAGEMENT, LLC | 330,000 | $492,000 | 0.52% |
| Orbimed Advisors | 3,493,800 | $5,206,000 | 0.08% |
| CALIBER WEALTH MANAGEMENT, LLC | 75,120 | $112,000 | 0.07% |
| Fort Sheridan Advisors LLC | 135,000 | $201,000 | 0.06% |
| AWM Investment Company, Inc. | 241,867 | $360,000 | 0.05% |
| WEALTH EFFECTS LLC | 49,000 | $73,000 | 0.03% |